MX2022000376A - Aminopirimidinas como inhibidores de alk. - Google Patents
Aminopirimidinas como inhibidores de alk.Info
- Publication number
- MX2022000376A MX2022000376A MX2022000376A MX2022000376A MX2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A
- Authority
- MX
- Mexico
- Prior art keywords
- aminopyrimidines
- alk inhibitors
- formula
- present disclosure
- provides compounds
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación proporciona compuestos representados por la Fórmula I: (ver Fórmula) y sus sales, hidratos y solvatos aceptables desde el punto de vista farmacéutico, en donde R1a, R1b, R2a, R2b, R3, R4, R5, R6 y R7 son como se definen en la memoria descriptiva. La presente divulgación también proporciona compuestos de la Fórmula I para usarse en el tratamiento de una afección o trastorno que responde a la inhibición de ALK tal como el cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380818P | 2016-08-29 | 2016-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000376A true MX2022000376A (es) | 2022-02-10 |
Family
ID=59846649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002393A MX389265B (es) | 2016-08-29 | 2017-08-28 | Aminopirimidinas como inhibidores de alk. |
| MX2022000376A MX2022000376A (es) | 2016-08-29 | 2019-02-27 | Aminopirimidinas como inhibidores de alk. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002393A MX389265B (es) | 2016-08-29 | 2017-08-28 | Aminopirimidinas como inhibidores de alk. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10709705B2 (es) |
| EP (2) | EP3504203B1 (es) |
| JP (2) | JP7094566B2 (es) |
| KR (1) | KR102530871B1 (es) |
| CN (2) | CN115043821B (es) |
| AU (2) | AU2017319135B2 (es) |
| IL (1) | IL264638B (es) |
| MX (2) | MX389265B (es) |
| NZ (1) | NZ751713A (es) |
| SG (2) | SG10201914030UA (es) |
| WO (1) | WO2018044767A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3758705A4 (en) * | 2018-07-31 | 2021-08-04 | Ascentage Pharma (Suzhou) Co., Ltd. | CANCER TREATMENT METHOD USING A COMBINATION OF FAK / ALK / ROS1 INHIBITOR AND EGFR INHIBITOR |
| CN111171033B (zh) * | 2018-11-09 | 2021-11-02 | 天津大学 | 一种嘧啶衍生物及其合成方法和应用 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN110143947B (zh) * | 2019-05-29 | 2021-10-15 | 华东师范大学 | 一种色瑞替尼类似物的制备方法 |
| CN113395968B (zh) * | 2019-06-25 | 2024-03-01 | 苏州亚盛药业有限公司 | 用于治疗疾病的fak抑制剂和btk抑制剂的组合 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN116261455B (zh) * | 2020-09-25 | 2024-11-01 | 苏州亚盛药业有限公司 | 一种药物组合物及其在治疗癌症中的用途 |
| WO2022222932A1 (en) * | 2021-04-19 | 2022-10-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| JP2024544576A (ja) * | 2021-12-09 | 2024-12-03 | オンコビクス・カンパニー・リミテッド | 癌細胞成長への抑制効果を示す新規ヘテロ環置換ピリミジン誘導体及びそれを含む医薬組成物 |
| CN116332919B (zh) * | 2022-03-30 | 2025-08-26 | 苏州亚盛药业有限公司 | 一种alk抑制剂化合物及其中间体的制备方法 |
| CN120513241A (zh) * | 2023-01-20 | 2025-08-19 | 苏州亚盛药业有限公司 | Alk抑制剂或其盐、溶剂合物的结晶形式及其制备方法和应用 |
| WO2024193693A1 (zh) * | 2023-03-22 | 2024-09-26 | 苏州亚盛药业有限公司 | 药物组合及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| DK2287156T3 (da) | 2003-08-15 | 2013-08-26 | Novartis Ag | 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet |
| JP2007505858A (ja) * | 2003-09-18 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン |
| RS52545B (sr) * | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| RS53588B1 (sr) | 2006-12-08 | 2015-02-27 | Irm Llc | Jedinjenja i kompozicije kao inhibitori protein kinaza |
| JP5298187B2 (ja) | 2008-04-07 | 2013-09-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| BR112013008816A2 (pt) | 2010-10-14 | 2016-06-28 | Ariad Pharma Inc | método de tratamento de câncer direcionado ao egfr resistente à erlotinibe ou gefitinibe, ou uso de um sal farmacêuticamente aceito em um indivíduo |
| KR101521861B1 (ko) | 2011-02-02 | 2015-05-21 | 노파르티스 아게 | Ａｌｋ 억제제의 사용 방법 |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
-
2017
- 2017-08-28 WO PCT/US2017/048845 patent/WO2018044767A2/en not_active Ceased
- 2017-08-28 CN CN202210533398.XA patent/CN115043821B/zh active Active
- 2017-08-28 US US15/559,445 patent/US10709705B2/en active Active
- 2017-08-28 MX MX2019002393A patent/MX389265B/es unknown
- 2017-08-28 JP JP2019511664A patent/JP7094566B2/ja active Active
- 2017-08-28 AU AU2017319135A patent/AU2017319135B2/en active Active
- 2017-08-28 NZ NZ751713A patent/NZ751713A/en unknown
- 2017-08-28 SG SG10201914030UA patent/SG10201914030UA/en unknown
- 2017-08-28 SG SG11201901251SA patent/SG11201901251SA/en unknown
- 2017-08-28 EP EP17764949.8A patent/EP3504203B1/en active Active
- 2017-08-28 EP EP21212760.9A patent/EP4001273A3/en not_active Withdrawn
- 2017-08-28 CN CN201780057518.0A patent/CN109715620B/zh active Active
- 2017-08-28 KR KR1020197007075A patent/KR102530871B1/ko active Active
-
2019
- 2019-02-04 IL IL264638A patent/IL264638B/en unknown
- 2019-02-27 MX MX2022000376A patent/MX2022000376A/es unknown
-
2020
- 2020-06-29 US US16/914,518 patent/US11110090B2/en active Active
-
2021
- 2021-05-14 AU AU2021203098A patent/AU2021203098B2/en active Active
-
2022
- 2022-06-15 JP JP2022096630A patent/JP2022120151A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115043821B (zh) | 2024-08-06 |
| AU2021203098A1 (en) | 2021-06-10 |
| WO2018044767A2 (en) | 2018-03-08 |
| MX2019002393A (es) | 2019-07-08 |
| CN115043821A (zh) | 2022-09-13 |
| SG11201901251SA (en) | 2019-03-28 |
| MX389265B (es) | 2025-03-20 |
| EP3504203A2 (en) | 2019-07-03 |
| JP2022120151A (ja) | 2022-08-17 |
| IL264638B (en) | 2021-08-31 |
| AU2017319135B2 (en) | 2021-03-18 |
| EP3504203B1 (en) | 2022-09-28 |
| US20200330464A1 (en) | 2020-10-22 |
| US11110090B2 (en) | 2021-09-07 |
| US10709705B2 (en) | 2020-07-14 |
| BR112019003897A2 (pt) | 2019-05-21 |
| AU2021203098B2 (en) | 2023-05-25 |
| EP4001273A2 (en) | 2022-05-25 |
| US20190175595A1 (en) | 2019-06-13 |
| SG10201914030UA (en) | 2020-03-30 |
| KR102530871B1 (ko) | 2023-05-09 |
| NZ751713A (en) | 2022-07-01 |
| CN109715620B (zh) | 2022-05-06 |
| CA3033223A1 (en) | 2018-03-08 |
| AU2017319135A1 (en) | 2019-04-04 |
| JP2019528307A (ja) | 2019-10-10 |
| JP7094566B2 (ja) | 2022-07-04 |
| WO2018044767A3 (en) | 2018-04-12 |
| KR20190039760A (ko) | 2019-04-15 |
| EP4001273A3 (en) | 2022-08-24 |
| CN109715620A (zh) | 2019-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000376A (es) | Aminopirimidinas como inhibidores de alk. | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| PH12019502263A1 (en) | Piperidines as covalent menin inhibitors | |
| MX2018012174A (es) | Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2). | |
| MX2023006257A (es) | Inhibidores de smyd. | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MD20160106A2 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| MX2020009887A (es) | Derivados de aminopiridina como inhibidores de ctps1. | |
| MX2017003930A (es) | Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank. | |
| PH12016501388A1 (en) | Heteroaryls and uses thereof | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| PH12015502018A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
| MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| MX2021004659A (es) | Derivados de aminopirimidina/pirazina como inhibidores de ctps1. | |
| PH12020551580A1 (en) | Piperidine compounds as covalent menin inhibitor-0s | |
| MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
| MA40170A (fr) | Dérivés hétérocycliques de morphinan et leur utilisation | |
| MX390051B (es) | Antagonistas de ep4. | |
| PH12021550374A1 (en) | Small molecule menin inhibitors | |
| MX2017005423A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
| MX2018001317A (es) | Inhibidores del virus sincitial respiratorio. | |
| MX2021015514A (es) | Compuesto heterociclico. |